Pyxis Tankers Announces Loan Commitment for Potential Fleet Expansion

Pyxis Tankers (PXS) will acquire the remaining 40% stake in the entity owning the Ormi vessel, a 2016-built Ultramax dry bulk ship. The deal, valued at $6.83 million, is expected to be immediately accretive and simplify ownership. The vessel was previously appraised at $32.08 million, with $15.0 million in debt.

Pyxis Tankers Inc. (PXS) furnished an SEC Form 6-K — earnings release. Exhibit 99.2 Pyxis Tankers Announces Financial Results for the Three & Six Months Ended June 30, 2026 Maroussi, Greece, August 31, 2026 – Pyxis Tankers Inc. (Nasdaq Cap Mkts: PXS), (the “Company”, “we”, “our”, “us” or “Pyxis Tankers”), an international diversified shipping compan

Cumberland Pharmaceuticals (CPIX) reported Phase 2a trial results for ifetroban in systemic sclerosis, showing safety and tolerability but no efficacy conclusions. Shares fell 17.55% in after-hours trading. The 12-month trial enrolled 41 patients, with most experiencing limited disease progression. Cumberland plans further studies to guide future development.

Amazon and Google signed 20-year deals with Constellation Energy for nuclear power, totaling $4.3B. Amazon secured 690 MW from Calvert Cliffs, while Google's deal covers 11 reactors. Critics question if these agreements will meet data center demand and impact household electricity costs. The Energy Department approved $4.4B in loans for nuclear facilities. Meta, Microsoft, and Amazon have also made significant nuclear power agreements.

Boeing (NYSE:BA) halted 777 freighter production for two months due to a supplier dispute with Vaero, costing up to $6.5M daily. The issue also impacted 767 aircraft production. Boeing is bringing manufacturing in-house and has removed two partially assembled 777 freighters from its assembly line. The 777X program is unaffected. Boeing has delivered 21 777 freighters this year, with more possible by 2026.

Moderna and Merck reported late-stage trial results showing their personalized mRNA melanoma vaccine, intismeran, reduced relapse risk by 42% when combined with Keytruda. The trial involved 1,137 patients, with 82% of vaccine recipients showing no recurrence after two years, compared to 70% for the placebo group. The companies plan to present the findings at a medical conference and continue long-term studies.